Eden Research Raises £10.8m Through Retail Offer and Placings to Expand Capital Base

Eden Research ( (GB:EDEN) ) just unveiled an announcement.

Eden Research has completed its recent Retail Offer, raising approximately £0.2 million through the issue of 3.76 million new shares at 4p, contributing to an aggregate £10.8 million gross fundraising via placings and subscriptions, subject to shareholder approval at a general meeting on 18 February 2026. If the necessary resolutions are passed and specified conditions are met, the company will issue a total of 270 million new ordinary shares in two stages, significantly enlarging its share capital and providing additional growth capital, although part of the placing remains conditional and may not complete if conditions are not satisfied by early May 2026, which introduces some uncertainty for investors over the final scale of the capital raise.

The most recent analyst rating on (GB:EDEN) stock is a Hold with a £4.00 price target. To see the full list of analyst forecasts on Eden Research stock, see the GB:EDEN Stock Forecast page.

Spark’s Take on GB:EDEN Stock

According to Spark, TipRanks’ AI Analyst, GB:EDEN is a Neutral.

The score is held back primarily by weak financial performance—ongoing losses and persistently negative operating/free cash flow—despite revenue growth and a relatively stable balance sheet. Technicals are supportive due to strong price momentum above key moving averages, but extremely overbought readings raise pullback risk. Valuation is neutral-to-cautious because the negative P/E reflects lack of profitability and there is no dividend yield data.

To see Spark’s full report on GB:EDEN stock, click here.

More about Eden Research

Eden Research plc is a UK-quoted company focused on sustainable biopesticides for agriculture, developing and supplying biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. Its terpene-based products, including the biofungicide Mevalone, the bionematicide Cedroz and the bird-repellent seed treatment Ecovelex, are primarily used on high-value fruit and vegetable crops, and are formulated using its plastic-free, biodegradable Sustaine encapsulation technology. Eden, which derives 100% of its revenue from green economy products and holds the London Stock Exchange’s Green Economy Mark, has been listed on AIM since 2012 under the ticker EDEN.

Average Trading Volume: 604,694

Technical Sentiment Signal: Buy

Current Market Cap: £21.6M

See more insights into EDEN stock on TipRanks’ Stock Analysis page.